Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Vaxxas raises $20M in B round

February 10, 2015 1:50 AM UTC

Vaxxas Pty. Ltd. (Sydney, Australia) raised $20 million (A$25.7 million) toward a planned $23.3 million (A$30 million) series B round led by existing investor OneVentures. Undisclosed new investors also participated.

CEO David Hoey said the company plans to begin clinical testing this year of its needle-free Nanopatch technology to deliver an approved flu vaccine with an undisclosed partner. Vaxxas has received funding from the World Health Organization to perform preclinical studies using Nanopatch to deliver polio vaccine. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article